Vol 51 No 09

FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk

Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer

Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC